Free tool
FAERS Monitor: Ziextenzo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761045 or its brand name (Ziextenzo, Pegfilgrastim-Bmez). Reports on generic versions are filed under their own applications.
Reports
607
Serious
506
83% of reports
Hospitalization
239
Death reported
190
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death133
- neutropenia49
- off label use48
- fatigue42
- nausea38
- vomiting37
- drug ineffective36
- sepsis34
- back pain32
- c-reactive protein increased29
- pyrexia29
- candida infection28
- restlessness28
- pleural effusion27
- brain oedema26
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 8 |
| 2020 | 46 |
| 2021 | 74 |
| 2022 | 120 |
| 2023 | 141 |
| 2024 | 120 |
| 2025 | 77 |
| 2026 | 21 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,552 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| brain oedemaSignal | 26 | 71.5 | 49.1 | 1,735 |
| candida infectionSignal | 28 | 57.5 | 40.1 | 1,498 |
| c-reactive protein increasedSignal | 29 | 27.6 | 19.4 | 719 |
| restlessnessSignal | 28 | 26.5 | 18.5 | 663 |
| pleural effusionSignal | 27 | 15.4 | 10.6 | 350 |
| neutropeniaSignal | 49 | 12.5 | 9.5 | 510 |
| sepsisSignal | 34 | 10.6 | 7.6 | 286 |
| deathSignal | 133 | 5.3 | 4.6 | 486 |
| back painSignal | 32 | 4.8 | 3.4 | 93 |
| pyrexiaSignal | 29 | 2.9 | 2.0 | 35 |
| vomitingSignal | 37 | 2.7 | 2.0 | 40 |
| off label use | 48 | 1.9 | 1.4 | 20 |
| fatigue | 42 | 1.9 | 1.4 | 17 |
| nausea | 38 | 1.7 | 1.2 | 10 |
| drug ineffective | 36 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.